This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Two siblings inherited the same rare genetic disease—a type of muscular dystrophy that progressively weakens the muscles of the face, shoulders and limbs. Although they shared the same disease-causing genetic change, their outcomes were strikingly different. The brother began noticing weakness in his early teens and could barely walk by his 50s. The sister remained symptom-free into her late 30s and was only mildly affected throughout her life.
The disease is facioscapulohumeral muscular dystrophy (FSHD). If you have the disease-causing genetic change, you will develop the disease—but it's been a long-standing mystery why some people are severely affected and others have relatively mild symptoms.
Now, research with a nine-generation family shows that the severity of FSHD is strongly influenced by a DNA modification called methylation, which acts like a "dimmer switch" at the disease-causing genetic change, making symptoms milder. The findings could help predict disease outcomes for patients, accelerate clinical trials and identify new therapeutic targets for treating or preventing FSHD.
"What's been unexplained through the years is the variability in symptoms among affected individuals," says Robert Weiss, Ph.D., professor of human genetics at University of Utah Health and senior author of the study. "Methylation had been suspected, but nobody had clearly unraveled it. This helps clarify a long-standing question in the field."
Scientists had known the cause of FSHD for years: a specific genetic change in a gene called DUX4 , which is normally active only during early embryonic development.
Source link







